

European Heart Journal

Volume 42 No. 47 December 2021

ISSUE @ A GLANCE



- An update on triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease
F. Crea 4777

CardioPulse

- The changing *Nature* of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn
P. Libby 4781

- Waiting for the light at the end of the COVID-19 tunnel: best and worst moments 1 year into the pandemic
M. Mapelli, S. Buzzi, and P. Maggioni 4783

- Nocebo/drugcebo effect in statin-intolerant patients: an attempt at recommendations
P.E. Penson and M. Banach 4787

Weekly Journal Scan

- FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease
G. Liuzzo and M. Volpe 4789

SPECIAL ARTICLE

- 8 Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
H.N. Ginsberg, C.J. Packard, M.J. Chapman, J. Borén, C.A. Aguilar-Salinas, M. Averna, B.A. Ference, D. Gaudet, R.A. Hegele, S. Kersten, G.F. Lewis, A.H. Lichtenstein, P. Moulin, B.G. Nordestgaard, A.T. Remaley, B. Staels, E.S.G. Stroes, M.-R. Taskinen, L.S. Tokgözoğlu, A. Tybjaerg-Hansen, J.K. Stock, and A.L. Catapano 4791

FAST TRACK CLINICAL RESEARCH

Dyslipidaemias

- A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs*
T. Doi, A. Langsted, and B.G. Nordestgaard 4807

Editorial

- Investigating contrasting results in REDUCE-IT and STRENGTH: partial answers but questions remain
K.C. Maki 4818

Dyslipidaemias

- Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial
K. Oyama, R.P. Giugliano, M. Tang, M.P. Bonaca, J.L. Saver, S.A. Murphy, A. Ruzza, A.C. Keech, P.S. Sever, M.S. Sabatine, and B.A. Bergmark 4821

Editorial

- PCSK9 inhibition for acute arterial events: more than LDL lowering
C.E. Orringer 4830

CLINICAL RESEARCH

Dyslipidaemias

- Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction
A. Varbo and B.G. Nordestgaard 4833

Editorial

- Lipoprotein remnants: to be or not to be
A. Pirillo and A.L. Catapano 4844

TRANSLATIONAL RESEARCH

Dyslipidaemias

Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms

X. Liu, J.-W. Guo, X.-C. Lin, Y.-H. Tuo, W.-L. Peng, S.-Y. He, Z.-Q. Li, Y.-C. Ye, J. Yu, F.-R. Zhang, M.-M. Ma, J.-Y. Shang, X.-F. Lv, A.-D. Zhou, Y. Ouyang, C. Wang, R.-P. Pang, J.-X. Sun, J.-S. Ou, J.-G. Zhou, and S.-J. Liang

4847

Editorial

Two birds, one stone: NFATc3 controls dual actions of miR-204 in foam cell formation

C. van Solingen and K.J. Moore

4862

DISCUSSION FORUM

-  The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
Ph.G. Steg and D.L. Bhatt

4865

Mineral oil and icosapent ethyl may jointly explain the between arm difference of cardiovascular risk in REDUCE-IT

T. Doi, A. Langsted, and B.G. Nordestgaard

4867

CARDIOVASCULAR FLASHLIGHT

In vivo paradoxical embolism during monitorization of extracorporeal membrane oxygenation implantation

L. Anmad Shihadeh, J.F. Ortega Restrepo, E. Aguilar Blanco, J. Solis, and C. Jiménez López Guarch

4869

A 'normotensive' adult with dysplastic double aortic arch

X. Li and H. Wang

4870

* This paper is the Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

Open Access Paper

 For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org